ArticleNature reviews. Clinical oncology2018
The new era of adjuvant therapies for melanoma.
Article in Nature reviews. Clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.Journal for immunotherapy of cancer · 2023Guideline
- Efficacy and safety of immune checkpoint inhibitors and targeted therapies in resected melanoma: a systematic review and network meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.Nature cancer · 2026Trial
- Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.Cancer discovery · 2022Trial
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Conditional disease-free survival in high-risk renal cell carcinoma treated with sunitinib.Aging · 2019Trial
- Baseline Red Blood Cell Distribution Width as a Prognostic Marker in High-Risk Resected Cutaneous Melanoma.Journal of clinical medicine · 2026Article
- Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).Journal of neurology · 2024Observational
- Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment.International journal of biological sciences · 2024Review
- Molecular characteristics and therapeutic implications of Toll-like receptor signaling pathway in melanoma.Scientific reports · 2023Article
- The role of mitochondria in the resistance of melanoma to PD-1 inhibitors.Journal of translational medicine · 2023Review
- Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis.Cancers · 2023Article
- Survival of patients with stage IIIC and IIID melanomas with nodal metastases in the light of new therapies.Postepy dermatologii i alergologii · 2022Article
- The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.Journal of translational medicine · 2022Article
- Article
- 3, 3'- (3, 5-DCPBC) Down-Regulates Multiple Phosphokinase Dependent Signal Transduction Pathways in Malignant Melanoma Cells through Specific Diminution of EGFRMolecules (Basel, Switzerland) · 2022Article
- Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts.Frontiers in immunology · 2022Article
- Article
- Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer.EMBO molecular medicine · 2021Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
29849093What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.